The dual shelf effectiveness removes a procedural barrier to raising capital. With weak analyst sentiment and minimal institutional support, the risk of a dilutive offering is elevated. Traders should watch for a prospectus supplement or 424B filing that would signal an actual offering — that event would likely pressure the stock.
Price Chart
Executive Summary
Esperion Therapeutics received SEC effectiveness on two shelf registration statements (File Nos. 333-201198 and 333-197125) on July 15, 2026. Both are now effective, giving the company the ability to offer and sell securities at any time. This creates a potential dilution overhang for common shareholders, as the company can tap the market without further notice.
Key Facts
- Two shelf registration statements (333-201198 and 333-197125) declared effective by the SEC on July 15, 2026.
- Both are 1933 Act filings, enabling Esperion to offer and sell securities (common stock, preferred stock, warrants, etc.) at its discretion.
- No specific offering size, pricing, or terms were disclosed in the effectiveness notices.
- The company has a market cap of approximately $819M and is covered by 0 Strong Buy ratings (0% bullish analyst consensus).
- Top institutional holder Wasatch Advisors holds only $6M, and recent 13F activity shows a near-exit move.
Financial Impact
Potential dilution of unknown size — shelf registrations allow for offerings up to undisclosed amounts. Any future offering could dilute existing common shareholders.
Risk Factors
- Potential dilutive equity offering at any time without prior notice.
- Weak analyst consensus (0% bullish) and low institutional conviction (Wasatch near-exit) suggest limited demand for the stock.
- Historical calibration shows score-5/6/7 reports on ESPR have low observed win rates (33-43%) at T+20, but the average loss magnitude is large (-17% to -19%), indicating asymmetric downside risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (ESPR) — Batch item 1 | 9999999995-26-002302 |
| Document: 9999999995-26-002302-index.html | 9999999995-26-002301 |
| Document: 9999999995-26-002302.txt | 9999999995-26-002302 |
| EFFECT Filing (ESPR) — Batch item 4 | 9999999995-26-002301 |
| Document: 9999999995-26-002301-index.html | 9999999995-26-002302 |
| Document: 9999999995-26-002301.txt | 9999999995-26-002302 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | — | awaiting T+5 | — | — |
Aug 13, 2026 7w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 23, 2026 10w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | ▼ −0.63% | ▲ +0.41% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | ▲ +0.63% | ▲ +0.20% | — |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | ▲ +0.64% | ▼ −2.80% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access